Ginsenoside Rp1 from Panax ginseng Exhibits Anti-cancer Activity by Down-regulation of the IGF-1R/Akt Pathway in Breast Cancer Cells

  • Ju-Hee Kang
  • Ki-Hoon Song
  • Jong-Kyu Woo
  • Myung Hwan Park
  • Man Hee Rhee
  • Changsun Choi
  • Seung Hyun Oh


Cancer prevention is effective and reduces health care costs because cancer is often a preventable disease that can be affected by lifestyle factors. Therefore, researchers are interested in discovering natural compounds that have anticancer activities, such as delaying the development of cancer and preventing its progression. One such natural agent is ginseng (Panax ginseng), which is traditionally used in some parts of the world as a popular remedy for various diseases including cancer. We hypothesized that the ginsenoside Rp1, a component of ginseng, reduces cancer cell proliferation through inhibition of the insulin-like growth factor 1 receptor (IGF-1R)/Akt pathway. We first tested the efficacy of Rp1 against human breast cancer cell lines. Treatment with Rp1 inhibited breast cancer cell proliferation and inhibited both anchorage-dependent and -independent breast cancer cell colony formation. In addition, treatment with 20 μM Rp1 induced cycle arrest and apoptosis-mediated cell growth suppression. Our findings further indicated that Rp1 decreased the stability of the IGF-1R protein in breast cancer cells. Therefore, we suggest that Rp1 has potential as an anticancer drug and that IGF-1R is an important target for treatment and prevention of breast cancer.


Akt Breast cancer Ginseng Ginsenoside Rp1 IGF-1R 



Dulbecco’s modified Eagle’s medium


fetal bovine serum


heat shock protein 90


insulin-like growth factor


IGF-1 receptor




matrix metalloproteinase


3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide


nuclear factor


polymerase chain reaction


phosphoinositide 3-kinase


reverse transcriptase


  1. 1.
    Linn SC, Pinedo HM, van Ark-Otte J, van der Valk P, Hoekman K, Honkoop AH, Vermorken JB, Giaccone G (1997) Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 71:787–795CrossRefGoogle Scholar
  2. 2.
    Hortobagyi GN, Piccart-Gebhart MJ (1996) Current management of advanced breast cancer. Semin Oncol 23:1–5Google Scholar
  3. 3.
    Glade MJ (1999) Food, nutrition, and the prevention of cancer: A global perspective. American Institute for Cancer Research/World Cancer Research Fund, American Institute for Cancer Research, 1997. Nutrition 15:523–526CrossRefGoogle Scholar
  4. 4.
    Gullett NP, Ruhul Amin AR, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR, Aggarwal BB, Surh YJ, Kucuk O (2010) Cancer prevention with natural compounds. Semin Oncol 37:258–281Google Scholar
  5. 5.
    Sen T, Dutta A, Chatterjee A (2010) Epigallocatechin-3-gallate (EGCG) downregulates gelatinase-B (MMP-9) by involvement of FAK/ERK/NFkappaB and AP-1 in the human breast cancer cell line MDA-MB-231. Anticancer Drugs 21:632–644Google Scholar
  6. 6.
    Murillo G, Peng X, Torres KE, Mehta RG (2009) Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway. Cancer Prev Res (Phila) 2:942–950CrossRefGoogle Scholar
  7. 7.
    Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218–220CrossRefGoogle Scholar
  8. 8.
    Yun TK (2001) Brief introduction of Panax ginseng C.A. Meyer. J Korean Med Sci 16(Suppl):S3–S5Google Scholar
  9. 9.
    Szeto YT, Wong JW, Wong SC, Pak SC, Benzie IF (2011) DNA protective effect of ginseng and the antagonistic effect of Chinese turnip: A preliminary study. Plant Foods Hum NutrGoogle Scholar
  10. 10.
    Cheung SC, Szeto YT, Benzie IF (2007) Antioxidant protection of edible oils. Plant Foods Hum Nutr 62:39–42CrossRefGoogle Scholar
  11. 11.
    Kang KS, Yamabe N, Kim HY, Park JH, Yokozawa T (2010) Effects of heat-processed ginseng and its active component ginsenoside 20(S)-Rg3 on the progression of renal damage and dysfunction in type 2 diabetic Otsuka Long-Evans Tokushima Fatty rats. Biol Pharm Bull 33:1077–1081Google Scholar
  12. 12.
    Helms S (2004) Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev 9:259–274Google Scholar
  13. 13.
    Li B, Wang CZ, He TC, Yuan CS, Du W (2010) Antioxidants potentiate American ginseng-induced killing of colorectal cancer cells. Cancer Lett 289:62–70Google Scholar
  14. 14.
    Cui Y, Shu XO, Gao YT, Cai H, Tao MH, Zheng W (2006) Association of ginseng use with survival and quality of life among breast cancer patients. Am J Epidemiol 163:645–653CrossRefGoogle Scholar
  15. 15.
    Park TY, Park MH, Shin WC, Rhee MH, Seo DW, Cho JY, Kim HM (2008) Anti-metastatic potential of ginsenoside Rp1, a novel ginsenoside derivative. Biol Pharm Bull 31:1802–1805CrossRefGoogle Scholar
  16. 16.
    Kumar A, Kumar M, Park TY, Park MH, Takemoto T, Terado T, Kitano M, Kimura H (2009) Molecular mechanisms of ginsenoside Rp1-mediated growth arrest and apoptosis. Int J Mol Med 24:381–386Google Scholar
  17. 17.
    Kim BH, Cho JY (2009) Regulatory role of ginsenoside Rp1, a novel ginsenoside derivative, on CD29-mediated cell adhesion. Planta Med 75:316–320CrossRefGoogle Scholar
  18. 18.
    Kim BH, Lee YG, Park TY, Kim HB, Rhee MH, Cho JY (2009) Ginsenoside Rp1, a ginsenoside derivative, blocks lipopolysaccharide-induced interleukin-1beta production via suppression of the NF-kappaB pathway. Planta Med 75:321–326CrossRefGoogle Scholar
  19. 19.
    Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB (1999) NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401:82–85CrossRefGoogle Scholar
  20. 20.
    Romashkova JA, Makarov SS (1999) NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401:86–90CrossRefGoogle Scholar
  21. 21.
    Chen H, Yan GC, Gishizky ML (1998) Identification of structural characteristics that contribute to a difference in antiapoptotic function between human insulin and insulin-like growth factor 1 receptors. Cell Growth Differ 9:939–947Google Scholar
  22. 22.
    Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915–928CrossRefGoogle Scholar
  23. 23.
    Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R (2008) Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. Mol Cancer Ther 7:2575–2588CrossRefGoogle Scholar
  24. 24.
    Cho JY, Yoo ES, Baik KU, Park MH, Han BH (2001) In vitro inhibitory effect of protopanaxadiol ginsenosides on tumor necrosis factor (TNF)-alpha production and its modulation by known TNF-alpha antagonists. Planta Med 67:213–218CrossRefGoogle Scholar
  25. 25.
    Kumar A, Kumar M, Panwar M, Samarth RM, Park TY, Park MH, Kimura H (2006) Evaluation of chemopreventive action of Ginsenoside Rp1. Biofactors 26:29–43CrossRefGoogle Scholar
  26. 26.
    Baserga R (1995) The insulin-like growth factor I receptor: A key to tumor growth? Cancer Res 55:249–252Google Scholar
  27. 27.
    Dunn SE, Torres JV, Oh JS, Cykert DM, Barrett JC (2001) Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Res 61:1367–1374Google Scholar
  28. 28.
    Luqman S, Pezzuto JM (2010) NFkappa B: A promising target for natural products in cancer chemoprevention. Phytother Res 24:949–963Google Scholar
  29. 29.
    Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431–436CrossRefGoogle Scholar
  30. 30.
    Martins AS, Ordonez JL, Garcia-Sanchez A, Herrero D, Sevillano V, Osuna D, Mackintosh C, Caballero G, Otero AP, Poremba C, Madoz-Gurpide J, de Alava E (2008) A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res 68:6260–6270CrossRefGoogle Scholar
  31. 31.
    Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ (2009) Targeting HSP90 for cancer therapy. Br J Cancer 100:1523–1529CrossRefGoogle Scholar
  32. 32.
    Brodt P, Samani A, Navab R (2000) Inhibition of the type I insulin-like growth factor receptor expression and signaling: Novel strategies for antimetastatic therapy. Biochem Pharmacol 60:1101–1107CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Ju-Hee Kang
    • 1
    • 2
  • Ki-Hoon Song
    • 1
  • Jong-Kyu Woo
    • 3
  • Myung Hwan Park
    • 4
  • Man Hee Rhee
    • 5
  • Changsun Choi
    • 2
  • Seung Hyun Oh
    • 1
  1. 1.Division of Cancer BiologyNational Cancer CenterGoyang-siRepublic of Korea
  2. 2.Department of Food and Nutrition, College of Human EcologyChung-Ang UniversityAnsungRepublic of Korea
  3. 3.Seoul National University, College of MedicineSeoulRepublic of Korea
  4. 4.Ambo InstituteSeoulRepublic of Korea
  5. 5.College of Veterinary MedicineKyungpook National UniversityDaeguRepublic of Korea

Personalised recommendations